title: No evidence of an association of ERCC1 and ERCC2 polymorphisms with clinical outcomes of platinum-based chemotherapies in non-small cell lung cancer: a meta-analysis.
abstract: BACKGROUND
  The nucleotide excision repair (NER) pathway modulates platinum-based chemotherapeutic efficacy by removing drug-induced DNA damage.
  
  
  METHODS
  To summarize published data on the association between NER genes and responses to platinum-based chemotherapies in non-small cell lung cancer (NSCLC), we performed a meta-analysis of 17 published studies of ERCC1 C118T/C8092A and ERCC2 Lys751Gln/Asp312Asn polymorphisms, including 2097 cancer patients. Primary outcomes included objective response (TR) (i.e., complete response+partial response vs. stable disease+progressive disease), progression-free survival (PFS) and overall survival (OS). We calculated odds ratio (OR) or hazard ratio (HR) with 95% confidence interval (CI) to estimate the risk or hazard.
  
  
  RESULTS
  We found that none of the ERCC1 C118T/C8092A and ERCC2 Lys751Gln/Asp312Asn polymorphisms alone was statistically significantly associated with objective response, PFS and OS in NSCLC patients.
  
  
  CONCLUSIONS
  There is no evidence to support the use of NER ERCC1 C118T/C8092A and ERCC2 Lys751Gln/Asp312Asn polymorphisms as prognostic predictors of platinum-based chemotherapies in NSCLC.
authors.affiliation: Department of Epidemiology, The University of Texas, M.D. Anderson Cancer Center, Houston, TX, USA.
authors.forename: Ming
authors.initials: M
authors.lastname: Yin
authors.forename: Jingrong
authors.initials: J
authors.lastname: Yan
authors.forename: Alexandra
authors.initials: A
authors.lastname: Voutsina
authors.forename: Carmelo
authors.initials: C
authors.lastname: Tibaldi
authors.forename: David C
authors.initials: DC
authors.lastname: Christiani
authors.forename: Rebecca S
authors.initials: RS
authors.lastname: Heist
authors.forename: Rafael
authors.initials: R
authors.lastname: Rosell
authors.forename: Richard
authors.initials: R
authors.lastname: Booton
authors.forename: Qingyi
authors.initials: Q
authors.lastname: Wei
mesh_terms: D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality / Q000473:pathology; D004268:DNA-Binding Proteins / Q000235:genetics*; D018572:Disease-Free Survival; D004720:Endonucleases / Q000235:genetics*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality / Q000473:pathology; D009367:Neoplasm Staging; D017671:Platinum Compounds / Q000627:therapeutic use*; D011110:Polymorphism, Genetic; D016019:Survival Analysis; D016896:Treatment Outcome; D051759:Xeroderma Pigmentosum Group D Protein / Q000235:genetics*
chemical_list: D004268:DNA-Binding Proteins; D017671:Platinum Compounds; C071447:ERCC1 protein, human; D004720:Endonucleases; D051759:Xeroderma Pigmentosum Group D Protein